News

The amount is payable upon closing of the transaction plus a potential future milestone payment of up to €300 million (both payments subject to customary adjustments). The acquisition

NBE-Therapeutics is engaged in developing antibody-drug conjugates (ADCs) and advancing targeted cancer therapies by using its immune stimulatory iADC platform. NBE-002, the company’s lead compound, is presently in

“We have continued to invest strategically in capacity, technology and expertise across our global network so we can accelerate innovation and enhance productivity for our customers,” said Mike Shafer,

The Phase III MONALEESA-7 trial evaluated Kisqali plus endocrine therapy (goserelin plus either an aromatase inhibitor or tamoxifen) as initial treatment compared to endocrine therapy alone in pre-

The BNT162b2 vaccine has been granted authorisation under Health Canada’s Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to Covid-19. Canada is

Royalty Pharma will provide BioCryst with an upfront cash payment of $125 million and will receive royalties of 8.75% on direct annual net sales of ORLADEYO up to

The company is investing ~US$32 million in the facility to keep up with expected demand based on current forecasts, including potential new opportunities. This expansion of more than

The interim analysis for the efficacy of the AZD1222 vaccine candidate was based on 11,636 volunteers accruing 131 symptomatic infections from the phase 3 trials in the UK

Sotorasib, which is claimed to be the first KRAS G12C inhibitor to enter the clinic, is being assessed in the wide clinical programme examining 10 combinations with global